Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, announces it has closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro’s merger with BioSymetrics is designed to enhance Renovaro’s data repository and biomarker discovery capabilities, as well as add in vivo validation and drug discovery to Renovaro’s AI powered biomarker and diagnostic platform.
Read the full article: Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine //
Source: https://www.globenewswire.com/news-release/2025/04/09/3058523/0/en/Renovaro-and-BioSymetrics-Close-Merger-to-Accelerate-AI-Driven-Biomarker-Discovery-and-Precision-Medicine.html